People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Emmaus Life Sciences, Inc. | — | Pharmaceuticals | Series B | $102.9M | $2.9M | 2020 |
| Aspira Women's Health Inc. | — | Biotechnology | Series C | $80.0M | $16.6M | 2025 |
Jane PINE WOOD at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jane PINE WOOD on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Jones | 1 | 19 |
| Jeffrey Cohen | 1 | 10 |
| John Pappajohn | 1 | 10 |
| James S. Burns | 1 | 5 |
| Geoffrey Harris | 1 | 4 |
| Daniel Hoffman | 1 | 4 |
| Robin Smith | 1 | 4 |
| James Burns | 1 | 4 |
| John F. Hamilton | 1 | 3 |
| STEFANIE CAVANAUGH | 1 | 3 |
| Lynn O'Connor Vos | 1 | 3 |
| Robert Dickey | 1 | 3 |
| David B. Jones | 1 | 3 |
| Richard Turner | 1 | 3 |
| Amir F. Heshmatpour | 1 | 3 |
| Thomas McLain | 1 | 2 |
| William Creech | 1 | 2 |
| James Crawford | 1 | 2 |
| Andrew Sassine | 1 | 2 |
| Richard W. Turner | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.